Go Pro
→ 100% overnight gains? (From The Oxford Club) (Ad)tc pixel Free BTTX Stock Alerts

Better Therapeutics (BTTX) Competitors

Better Therapeutics logo
$0.0001 0.00 (0.00%)
As of 09/8/2026 09:30 AM Eastern
Compare

BTTX vs. UPHL, VRAYQ, IMAC, WINT, and NAVB

Should you buy Better Therapeutics stock or one of its competitors? Better Therapeutics's main competitors and comparable companies include UpHealth (UPHL), ViewRay (VRAYQ), IMAC (IMAC), Windtree Therapeutics (WINT), and Navidea Biopharmaceuticals (NAVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Better Therapeutics compare to UpHealth?

UpHealth (NYSE:UPHL) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

UpHealth has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

56.1% of UpHealth shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 34.2% of UpHealth shares are held by company insiders. Comparatively, 51.4% of Better Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Better Therapeutics has lower revenue, but higher earnings than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UpHealth$130M0.00-$56.42M$1.980.00
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

In the previous week, UpHealth's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
UpHealth Neutral
Better Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
UpHealthN/A N/A N/A
Better Therapeutics N/A N/A N/A

Summary

UpHealth beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Better Therapeutics compare to ViewRay?

Better Therapeutics (NASDAQ:BTTX) and ViewRay (NASDAQ:VRAYQ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Better Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, ViewRay has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
ViewRay Neutral

Better Therapeutics has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
ViewRay$102.21M0.00-$107.33MN/AN/A

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
ViewRay N/A N/A N/A

Summary

Better Therapeutics beats ViewRay on 5 of the 6 factors compared between the two stocks.

How does Better Therapeutics compare to IMAC?

IMAC (NASDAQ:IMAC) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

24.3% of IMAC shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 10.0% of IMAC shares are owned by company insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.00-$10.54M-$0.27N/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

In the previous week, IMAC had 4 more articles in the media than Better Therapeutics. MarketBeat recorded 4 mentions for IMAC and 0 mentions for Better Therapeutics. IMAC's average media sentiment score of 0.08 beat Better Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
Better Therapeutics Neutral

IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Better Therapeutics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Better Therapeutics' return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
Better Therapeutics N/A N/A N/A

Summary

Better Therapeutics beats IMAC on 7 of the 12 factors compared between the two stocks.

How does Better Therapeutics compare to Windtree Therapeutics?

Windtree Therapeutics (NASDAQ:WINT) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
Windtree Therapeutics Neutral
Better Therapeutics Neutral

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by company insiders. Comparatively, 51.4% of Better Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Better Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

Better Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Windtree TherapeuticsN/A -207.34% -50.19%
Better Therapeutics N/A N/A N/A

Windtree Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Summary

Better Therapeutics beats Windtree Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Better Therapeutics compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Better Therapeutics Neutral

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Navidea Biopharmaceuticals has higher revenue and earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Better Therapeutics N/A N/A N/A

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Navidea Biopharmaceuticals beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

Get Better Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTTX vs. The Competition

Export
MetricBetter TherapeuticsHealth services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$923.67K$7.22B$12.88B
Dividend YieldN/AN/A2.55%9.95%
P/E Ratio0.00N/A271.7925.29
Price / SalesN/A0.00709.72113.02
Price / CashN/AN/A77.5552.32
Price / BookN/A0.0010.636.26
Net Income-$39.76M-$48.09M$3.48B$357.86M
7 Day PerformanceN/AN/A-1.19%-0.56%
1 Month PerformanceN/AN/A1.99%-1.04%
1 Year PerformanceN/AN/A21.89%11.31%

Better Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTTX
Better Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
-66.7%		N/A-50.0%$2K$130MN/A1,750
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A300
IMAC
IMAC
N/A$0.00
flat		N/A-99.2%$13K$15.22MN/A106
WINT
Windtree Therapeutics
N/A$0.00
flat		N/A-99.7%$13KN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BTTX) was last updated on 9/10/2026 by MarketBeat.com Staff.
From Our Partners
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
What Is A Roth Conversion, And How Do I Set One Up?
A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...
SmartAsset | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...
Banyan Hill Publishing | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel